Article

In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of cystic fibrosis patients.

Center of Cystic Fibrosis, Cliniques universitaires Saint-Luc, Université Catholique de Louvain (UCL), Brussels, Belgium.
Journal of Cystic Fibrosis (impact factor: 3.19). 09/2005; 4(3):183-7. DOI:10.1016/j.jcf.2005.06.001 pp.183-7
Source: PubMed

ABSTRACT Home-nebulizers are a potential source of bacterial infection of the respiratory tract in patients suffering from cystic fibrosis. Recommendations for disinfecting this equipment are often arbitrary and sometimes contradictory.
To assess in vitro the effectiveness of 5 methods of disinfecting this equipment.
160 mouthpieces and 160 masks of nebulizers were artificially and massively contaminated with 16 strains of germs found in patients with cystic fibrosis (Staphylococcus aureus, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cenocepacia, Alcaligenes xylosoxydans). A controlled comparison was carried out of the five methods of disinfection (hypochlorite solution (0.02% active chlorine), acetic acid 3.5%, Hexanios 0.5%, washing-up detergent 0.5% and a dishwasher), tested with and without drying. Standardised bacteriological sampling took place 4 h after disinfecting.
Following treatment, the disappearance of the germ was recorded in 84.1% of cases, and effective disinfecting (reduction>5 log CFU/mL) in another 10.6%. Disinfection failure (5.3%) was found almost only in the case of acetic acid against Staphylococcus aureus.
With the exception of acetic acid, the methods of disinfecting tested in this study appeared to be effective against common bacterial pathogens in cystic fibrosis.

0 0
 · 
0 Bookmarks
 · 
11 Views
  • Source
    Article: Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.
    Harry Heijerman, Elsbeth Westerman, Steven Conway, Daan Touw, Gerd Döring
    [show abstract] [hide abstract]
    ABSTRACT: In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.
    Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 07/2009; 8(5):295-315. · 3.19 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

10.6%. Disinfection failure
 
16 strains
 
160 mouthpieces
 
5 methods
 
acetic acid
 
Burkholderia cenocepacia
 
cases
 
common bacterial pathogens
 
controlled comparison
 
disinfection
 
effective disinfecting
 
Home-nebulizers
 
place 4 h
 
potential source
 
Pseudomonas aeruginosa
 
reduction>5 log CFU/mL
 
Standardised bacteriological sampling
 
Staphylococcus aureus
 
Stenotrophomonas maltophilia
 
washing-up detergent 0.5%